{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:18:14Z","timestamp":1784305094883,"version":"3.55.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.antiviral.2020.104863","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T11:57:15Z","timestamp":1594900635000},"page":"104863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig"],"prefix":"10.1016","volume":"181","author":[{"given":"Thomas R.","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Freiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dyall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5796-532X","authenticated-orcid":false,"given":"Manu","family":"Anantpadma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Madrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5790","authenticated-orcid":false,"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104863_bib1","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/AAC.00543-16","article-title":"Large-scale screening and identification of novel Ebola virus and Marburg virus entry inhibitors","volume":"60","author":"Anantpadma","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104863_bib2","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1021\/acsomega.8b02948","article-title":"Ebola virus Bayesian machine learning models enable new in vitro leads","volume":"4","author":"Anantpadma","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.antiviral.2020.104863_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.xphs.2018.09.010","article-title":"Drug repurposing for Ebola virus disease: principles of consideration and the Animal Rule","volume":"108","author":"Bai","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.antiviral.2020.104863_bib3","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104863_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2020.104863_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","article-title":"Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus","volume":"151","author":"Bixler","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104863_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2020.104863_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4939-7116-9_4","article-title":"Production of filovirus glycoprotein-pseudotyped vesicular stomatitis virus for study of filovirus entry mechanisms","volume":"1628","author":"Brouillette","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2020.104863_bib10","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/s41467-019-11239-0","article-title":"Antimalarial activity of primaquine operates via a two-step biochemical relay","volume":"10","author":"Camarda","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2020.104863_bib11","doi-asserted-by":"crossref","first-page":"S603","DOI":"10.1093\/infdis\/jiy329","article-title":"Efficacy of Ebola glycoprotein-specific equine polyclonal antibody product against lethal Ebola virus infection in Guinea pigs","volume":"218","author":"Chan","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104863_bib12","first-page":"1466","article-title":"Axl inhibitor R428 induces apoptosis of cancer cells by blocking lysosomal acidification and recycling independent of Axl inhibition","volume":"8","author":"Chen","year":"2018","journal-title":"Am. J. Canc. Res."},{"key":"10.1016\/j.antiviral.2020.104863_bib13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1023\/A:1014515516381","article-title":"Study of the pathogenesis of Ebola fever in laboratory animals with different sensitivity to this virus","volume":"132","author":"Chepurnov","year":"2001","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2020.104863_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/v11020137","article-title":"Filovirus virulence in Interferon alpha\/beta and gamma Double Knockout mice, and treatment with favipiravir","volume":"11","author":"Comer","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2020.104863_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166318","article-title":"Evaluation of the activity of lamivudine and zidovudine against Ebola virus","volume":"11","author":"Cong","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104863_bib16","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2020.104863_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1475-2875-11-270","article-title":"Review of pyronaridine anti-malarial properties and product characteristics","volume":"11","author":"Croft","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.antiviral.2020.104863_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/v8110277","article-title":"Antiviral screening of multiple compounds against Ebola virus","volume":"8","author":"Dowall","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2020.104863_bib19","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1099\/jgv.0.000309","article-title":"Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo Guinea pig model","volume":"96","author":"Dowall","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2020.104863_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/cb6001202","article-title":"A new approach for enhancing differential selectivity of drugs to cancer cells","volume":"1","author":"Duvvuri","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.antiviral.2020.104863_bib21","doi-asserted-by":"crossref","first-page":"S592","DOI":"10.1093\/infdis\/jiy345","article-title":"In vitro and in vivo activity of amiodarone against Ebola virus","volume":"218","author":"Dyall","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104863_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau3174","article-title":"Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay","volume":"11","author":"Dziekan","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2020.104863_bib23","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.12688\/f1000research.7217.1","article-title":"Machine learning models identify molecules active against Ebola virus in vitro","volume":"4","author":"Ekins","year":"2015","journal-title":"F1000Research"},{"key":"10.1016\/j.antiviral.2020.104863_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01711-17","article-title":"Efficacy of tilorone dihydrochloride against Ebola virus infection","volume":"62","author":"Ekins","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104863_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.12688\/f1000research.6181.1","article-title":"Finding small molecules for the 'next Ebola","volume":"4","author":"Ekins","year":"2015","journal-title":"F1000Research"},{"key":"10.1016\/j.antiviral.2020.104863_bib27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drudis.2011.02.016","article-title":"In silico repositioning of approved drugs for rare and neglected diseases","volume":"16","author":"Ekins","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2020.104863_bib28","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0306-3623(96)00150-4","article-title":"Drug-induced lysosomal storage of sulphated glycosaminoglycans","volume":"27","author":"Fischer","year":"1996","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104863_bib29","first-page":"291","article-title":"[Outbreak of Ebola hemorrhagic fever in the Republic of the Congo, 2003: a new strategy?]","volume":"63","author":"Formenty","year":"2003","journal-title":"Med. Trop."},{"key":"10.1016\/j.antiviral.2020.104863_bib30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1039\/C6MD00589F","article-title":"Aryl-alkyl-lysines: small molecular membrane-active antiplasmodial agents","volume":"8","author":"Ghosh","year":"2017","journal-title":"MedChemComm"},{"key":"10.1016\/j.antiviral.2020.104863_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002535","article-title":"Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques","volume":"15","author":"Guedj","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2020.104863_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-018-2558-3","article-title":"High throughput and computational repurposing for neglected diseases","volume":"36","author":"Hernandez","year":"2018","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.antiviral.2020.104863_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/235050a0","article-title":"Lysosomes, pH and the anti-malarial action of chloroquine","volume":"235","author":"Homewood","year":"1972","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2020.104863_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbrc.2008.09.121","article-title":"Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes","volume":"377","author":"Ikeda","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104863_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMsr1904253","article-title":"The ongoing Ebola epidemic in the democratic republic of Congo, 2018-2019","volume":"381","author":"Ilunga Kalenga","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104863_bib36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0378-4347(96)00410-0","article-title":"Determination of pyronaridine in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies","volume":"690","author":"Jayaraman","year":"1997","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.antiviral.2020.104863_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2020.104863_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/d41586-019-02415-9","article-title":"Pandemic bonds: designed to fail in Ebola","volume":"572","author":"Jonas","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2020.104863_bib39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/infdis\/jiz078","article-title":"Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015-A retrospective observational study","volume":"220","author":"Kerber","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104863_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000149300","article-title":"Filoviridae: a taxonomic home for Marburg and Ebola viruses?","volume":"18","author":"Kiley","year":"1982","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2020.104863_bib41","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.antiviral.2020.104863_bib43","doi-asserted-by":"crossref","first-page":"e01142","DOI":"10.1128\/AAC.01142-19","article-title":"Repurposing quinacrine against Ebola virus infection in vivo","volume":"63","author":"Lane","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104863_bib45","doi-asserted-by":"crossref","first-page":"e0007890","DOI":"10.1371\/journal.pntd.0007890","article-title":"Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection","volume":"13","author":"Lane","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2020.104863_bib46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12879-019-3980-9","article-title":"Anti-Ebola therapy for patients with Ebola virus disease: a systematic review","volume":"19","author":"Lee","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104863_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13054-016-1325-2","article-title":"Ebola virus disease and critical illness","volume":"20","author":"Leligdowicz","year":"2016","journal-title":"Crit. Care"},{"key":"10.1016\/j.antiviral.2020.104863_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses","volume":"61","author":"Madelain","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104863_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060579","article-title":"A systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104863_bib50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104863_bib52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/abbi.1999.1506","article-title":"Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver","volume":"372","author":"Mankowski","year":"1999","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.antiviral.2020.104863_bib53","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1126\/science.1175667","article-title":"Chloroquine transport via the malaria parasite's chloroquine resistance transporter","volume":"325","author":"Martin","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2020.104863_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167018","article-title":"Minimal in vivo efficacy of iminosugars in a lethal Ebola virus Guinea pig model","volume":"11","author":"Miller","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104863_bib55","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1128\/AAC.02716-14","article-title":"Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol","volume":"58","author":"Morris","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104863_bib56","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104863_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104863_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2020.104863_bib59","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1128\/JVI.00422-09","article-title":"Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors","volume":"83","author":"Quinn","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104863_bib60","doi-asserted-by":"crossref","first-page":"S649","DOI":"10.1093\/infdis\/jiy303","article-title":"Postexposure protective efficacy of T-705 (favipiravir) against Sudan virus infection in Guinea pigs","volume":"218","author":"Rahim","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104863_bib61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jchromb.2005.06.034","article-title":"A new and simple solid-phase extraction method for LC determination of pyronaridine in human plasma","volume":"824","author":"Ramanathan","year":"2005","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.antiviral.2020.104863_bib62","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","article-title":"Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans","volume":"27","author":"Rijal","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2020.104863_bib63","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s002040050403","article-title":"Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, Guinea pigs, dogs, monkeys, and humans","volume":"71","author":"Shimada","year":"1997","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.antiviral.2020.104863_bib64","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104863_bib65","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2020.104863_bib67","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1473-3099(18)30397-9","article-title":"Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study","volume":"18","author":"Sivapalasingam","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104863_bib68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104863_bib69","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430 - a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.antiviral.2020.104863_bib70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/excr.2002.5613","article-title":"Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages","volume":"281","author":"Tyteca","year":"2002","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.antiviral.2020.104863_bib71","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/viro.2000.0572","article-title":"Molecular characterization of Guinea pig-adapted variants of Ebola virus","volume":"277","author":"Volchkov","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2020.104863_bib72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.chom.2018.12.004","article-title":"Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection","volume":"25","author":"Wec","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2020.104863_bib73","doi-asserted-by":"crossref","first-page":"30422","DOI":"10.18632\/oncotarget.16503","article-title":"The innate immunity of Guinea pigs against highly pathogenic avian influenza virus infection","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:40Z","timestamp":1759062700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":67,"alternative-id":["S0166354220302771"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104863","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.20.001081","asserted-by":"object"}]},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104863"}}